The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Metabolic manipulation in ischaemic heart disease, a novel approach to treatment
Abstract
Antianginal drugs that exert their anti-ischaemic effects primarily by altering myocardial metabolism have recently attracted attention. They have the potential to relieve symptoms in patients with refractory angina who are already on "optimal" medical therapy and have disease that is not amenable to revascularisation, making these drugs an attractive addition to therapy, particularly for the elderly population. In some cases, they may even be used as first-line treatment. These drugs increase glucose metabolism at the expense of free-fatty-acid metabolism, enhancing oxygen efficiency during myocardial ischaemia. Whilst they have been demonstrated to reduce ischaemia in several clinical trials, their use remains limited. This review aims to draw attention to these "metabolic" antianginal drugs while surveying the evidence supporting their use and mode of action. Four metabolic antianginal drugs are reviewed: perhexiline, trimetazidine, ranolazine, and etomoxir. We also discuss the metabolic actions of glucose-insulin-potassium and beta-blockers and describe myocardial metabolism during normal and ischaemic conditions. The potential of these metabolic agents may extend beyond the treatment of ischaemia secondary to coronary artery disease. They offer significant promise for the treatment of symptoms occurring due to inoperable aortic stenosis, hypertrophic cardiomyopathy, and chronic heart failure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ranolazine stimulates glucose oxidation in normoxic, ischemic, and reperfused ischemic rat hearts
McCormack, J. G., Barr, R. L., Wolff, A. A., & Lopaschuk, G. D. (1996) · Circulation · doi:10.1161/01.cir.93.1.135 · Cited by 291
Malmberg, K., Ryden, L., Hamstent, A., Herlitz, J., Waldenstrom, A., Wedel, H., & on behalf of the DIGAMI study group (1996) · European Heart Journal · doi:10.1093/oxfordjournals.eurheartj.a015067 · Cited by 281
Cited by
Myocardial Fatty Acid Metabolism in Health and Disease
Lopaschuk, G. D., Ussher, J. R., Folmes, C. D. L., Jaswal, J. S., & Stanley, W. C. (2010) · Physiological Reviews · doi:10.1152/physrev.00015.2009 · Cited by 2,179
Frantz, S., Hundertmark, M. J., Schulz-Menger, J., Bengel, F. M., & Bauersachs, J. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac223 · Cited by 606
Metabolic Mechanisms in Heart Failure
Ashrafian, H., Frenneaux, M. P., & Opie, L. H. (2007) · Circulation · doi:10.1161/circulationaha.107.702795 · Cited by 521
Screen for Chemical Modulators of Autophagy Reveals Novel Therapeutic Inhibitors of mTORC1 Signaling
Balgi, A. D., Fonseca, B. D., Donohue, E., Tsang, T. C. F., Lajoie, P., Proud, C. G., Nabi, I. R., & Roberge, M. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007124 · Cited by 344
“This inhibition shifts myocardial substrate utilization from fatty acids to lactate and glucose, which increases ATP generation per unit oxygen consumed and exerts an oxygen sparing effect on the heart muscle[80,82,83].”
BackgroundInfluentialMitochondria as a Drug Target in Ischemic Heart Disease and Cardiomyopathy
Walters, A. M., Porter, G. A., & Brookes, P. S. (2012) · Circulation Research · doi:10.1161/circresaha.112.265660 · Cited by 271
Metadata
- Authors
- Lee, L.
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-04
- Volume
- 25
- Issue
- 8
- Pages
- 634-641
- ISSN
- 0195-668X (ISSN-L)
- OpenAlex
- W2043025141
- Cited by
- 180
- References
- 2
- FWCI
- 8.47
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Metabolic manipulation in ischaemic heart disease, a novel approach to treatment. https://app.cochat.ai/papers/10.1016/j.ehj.2004.02.018
- The paper
- Lee, L. (2004). Metabolic manipulation in ischaemic heart disease, a novel approach to treatment. European Heart Journal. https://doi.org/10.1016/j.ehj.2004.02.018
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.